I-Derm Pharma

Company Overview

Snapshot

Founded in January 2022 by Ofer Sarig and Eli Sprecher, I-Derm Pharma operates with 1–10 employees. The company secured its first funding round in January 2022 from NGT HealthCare II, focusing on advancing its lead candidate for inflammatory autoimmune skin diseases.

Business overview

I-Derm Pharma is a Health Tech & Life Sciences company specializing in the development of first-in-class oral therapies for inflammatory autoimmune skin diseases, with a primary focus on moderate-to-severe psoriasis. The company's core technology involves a proprietary small-molecule family that targets a specific inflammatory pathway, demonstrating strong preclinical efficacy. I-Derm Pharma serves the pharmaceutical and healthcare markets, operating within the Drugs Discovery & Development sector.

Company Intelligence Q&A

What is I-Derm Pharma's primary focus?

I-Derm Pharma is focused on developing a first-in-class oral therapy for moderate-to-severe psoriasis, targeting inflammatory autoimmune skin diseases.

Who are the co-founders of I-Derm Pharma?

I-Derm Pharma was co-founded by Ofer Sarig, who serves as Co-founder & Scientific Advisor, and Eli Sprecher, who is Co-founder & Scientific and Clinical Advisor.

When was I-Derm Pharma founded?

I-Derm Pharma was founded in January 2022.

What type of product is I-Derm Pharma developing?

I-Derm Pharma is developing a proprietary small-molecule family as an oral therapy, which has shown strong preclinical efficacy in treating psoriatic human skin grafts.